Concerns about potential product liability from contamination of Johnson & Johnson’s baby powder sparked a nasty selloff in the company’s stock late last year. Fourth-quarter results from J&J on Tuesday highlight a more immediate risk: slowing growth. The results themselves were strong enough: Sales of $20.4 billion and adjusted earnings of $1.97 a share both topped analyst expectations. The company’s revenue forecast for 2019 wasn’t as good, however. The range implies little or no sales growth this year and its shares...

Source: Wall Street Journal January 22, 2019 17:01 UTC